Ben is a senior editor for BioPharma Dive. He is a veteran business journalist with 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
167 articles by Ben Fidler
-
Lilly expands its cancer drug work with bet on dual-acting antibodies
Jan. 19, 2021 -
US pushes for wider use of 'underutilized' COVID-19 antibody drugs as pandemic worsens
Jan. 15, 2021 -
JPM21: Vaccines soar, antibodies struggle as COVID-19 drugs become a business
Jan. 12, 2021 -
JPM21: Biogen faces make-or-break year, Vertex mulls deals and Sarepta pitches a silver lining
Jan. 11, 2021 -
Bluebird to split company, spin off cancer drug business
Jan. 11, 2021 -
10 key clinical trials to watch in the first half of 2021
Jan. 11, 2021 -
Roche adds to RNA drug deal streak with Ribometrix partnership
Jan. 6, 2021 -
5 FDA approval decisions to watch in the 1st quarter
Jan. 5, 2021 -
FDA says changing coronavirus vaccine dosing could put 'public health at risk'
Jan. 5, 2021 -
UK authorizes AstraZeneca, Oxford coronavirus vaccine, but questions linger
Dec. 30, 2020 -
US pays another $2B to buy more doses of Pfizer, BioNTech coronavirus vaccine
Dec. 23, 2020 -
Vertex teams up with Skyhawk, leaning on another biotech in bid to diversify
Dec. 22, 2020 -
Moderna's first FDA clearance brings the US a second coronavirus vaccine
Dec. 18, 2020 -
A play-by-play of the FDA meeting on Moderna's coronavirus vaccine
Dec. 17, 2020 -
Allogene, broadening its reach, helps start a biotech in China
Dec. 15, 2020 -
Sanofi, GSK coronavirus vaccine delayed after early study disappoints
Dec. 11, 2020 -
A play-by-play of the historic FDA meeting on Pfizer and BioNTech's coronavirus vaccine
Dec. 9, 2020 -
Biotech of the Year: Seagen
Dec. 9, 2020 -
In multiple myeloma, cell therapies lead but antibody drugs could follow fast
Dec. 8, 2020 -
Bayer strikes a deal with Atara, wading deeper into cell therapy
Dec. 7, 2020 -
A CRISPR gene editing treatment continues to show promise for two blood diseases
Dec. 5, 2020 -
4 storylines to track at the year's biggest meeting on blood diseases
Dec. 3, 2020 -
Ovid's plan to prove a shelved sleeping pill for a rare disease ends in disappointment
Dec. 2, 2020 -
With anemia data, Agios blood disease drug takes a crucial step forward
Dec. 1, 2020 -
Moderna, finishing key study, to ask FDA for emergency approval of coronavirus vaccine
Nov. 30, 2020